Profile data is unavailable for this security.
About the company
KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The Company is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.
- Revenue in USD (TTM)0.00
- Net income in USD-141.77m
- Incorporated2004
- Employees150.00
- LocationKalvista Pharmaceuticals Inc55 Cambridge Pkwy Ste 901ECAMBRIDGE 02142-1234United StatesUSA
- Phone+1 (857) 999-0075
- Fax+1 (302) 531-3150
- Websitehttps://www.kalvista.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Theravance Biopharma Inc | 62.02m | -45.65m | 387.95m | 99.00 | -- | 2.00 | -- | 6.26 | -0.924 | -0.924 | 1.25 | 3.96 | 0.1534 | -- | 4.12 | 626,434.30 | -11.29 | -40.51 | -12.00 | -48.50 | -- | -- | -73.61 | -305.27 | -- | -- | 0.1305 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
Esperion Therapeutics Inc | 277.79m | -98.50m | 406.19m | 240.00 | -- | -- | -- | 1.46 | -0.8758 | -0.8758 | 1.84 | -1.77 | 0.9466 | 0.7763 | 5.49 | 1,157,450.00 | -33.56 | -69.45 | -64.71 | -101.81 | 81.82 | -- | -35.46 | -147.44 | 1.49 | 0.0972 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
Elite Pharmaceuticals Inc | 66.45m | 19.58m | 430.83m | 64.00 | 21.08 | 7.40 | 20.46 | 6.48 | 0.0191 | 0.0191 | 0.064 | 0.0545 | 0.9892 | 2.91 | 4.98 | 1,038,252.00 | 29.15 | 19.07 | 36.18 | 24.29 | 45.27 | 46.63 | 29.47 | 20.77 | 2.09 | 1.44 | 0.1389 | 0.00 | 65.79 | 49.55 | 464.56 | -- | 111.50 | -- |
Xeris Biopharma Holdings Inc | 181.41m | -59.56m | 438.06m | 377.00 | -- | -- | -- | 2.41 | -0.4215 | -0.4215 | 1.28 | -0.1295 | 0.5493 | 0.7428 | 4.99 | 481,201.60 | -18.04 | -43.60 | -23.57 | -56.57 | 83.72 | 78.23 | -32.83 | -143.08 | 1.69 | -1.59 | 1.09 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
Zevra Therapeutics Inc | 23.99m | -65.75m | 440.41m | 65.00 | -- | 10.82 | -- | 18.36 | -1.67 | -1.67 | 0.6106 | 0.7734 | 0.1919 | -- | 2.09 | 369,015.40 | -52.61 | -32.11 | -65.34 | -39.89 | 71.78 | -- | -274.10 | -128.42 | -- | -112.94 | 0.6423 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
Aquestive Therapeutics Inc | 58.36m | -25.72m | 447.56m | 135.00 | -- | -- | -- | 7.67 | -0.3565 | -0.3565 | 0.7874 | -0.3896 | 0.6685 | 2.85 | 7.25 | 432,296.30 | -29.46 | -76.63 | -42.14 | -123.85 | 68.49 | 64.24 | -44.07 | -102.95 | 6.98 | -2.67 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
Eyepoint Pharmaceuticals Inc | 50.39m | -86.82m | 453.83m | 121.00 | -- | 1.94 | -- | 9.01 | -1.80 | -1.80 | 1.08 | 4.38 | 0.2016 | 1.10 | 8.18 | 416,454.50 | -34.74 | -40.44 | -47.07 | -47.79 | 91.35 | 83.45 | -172.29 | -186.23 | 4.69 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
SIGA Technologies Inc | 172.96m | 83.97m | 476.03m | 45.00 | 5.74 | 2.84 | 5.63 | 2.75 | 1.16 | 1.16 | 2.41 | 2.35 | 1.02 | 0.5866 | 23.09 | 3,843,484.00 | 49.52 | 22.34 | 56.21 | 27.56 | 82.00 | 88.65 | 48.55 | 41.14 | 5.65 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
Kalvista Pharmaceuticals Inc | 0.00 | -141.77m | 484.45m | 150.00 | -- | 2.79 | -- | -- | -3.54 | -3.54 | 0.00 | 4.01 | 0.00 | -- | -- | 0.00 | -78.65 | -40.63 | -87.52 | -43.67 | -- | -- | -- | -2,972.81 | -- | -- | 0.00 | -- | -- | -- | -36.31 | -- | -16.34 | -- |
Emergent Biosolutions Inc | 1.10bn | -587.00m | 498.06m | 1.60k | -- | 1.26 | -- | 0.4519 | -11.24 | -11.24 | 21.13 | 7.30 | 0.597 | 2.39 | 4.53 | 688,875.00 | -31.80 | -2.94 | -49.34 | -3.66 | 27.18 | 53.24 | -53.26 | -5.95 | 0.5438 | -1.87 | 0.6906 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
SNDL Inc | 668.22m | -82.73m | 514.25m | 2.52k | -- | 0.5699 | -- | 0.7696 | -0.3167 | -0.3167 | 2.55 | 3.40 | 0.5988 | 4.63 | 33.15 | 265,588.90 | -7.67 | -24.44 | -8.32 | -27.94 | 25.04 | 22.49 | -12.82 | -62.17 | 2.98 | -- | 0.1125 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
CorMedix Inc | 806.12k | -53.12m | 540.17m | 82.00 | -- | 11.57 | -- | 670.08 | -0.9262 | -0.9262 | 0.0141 | 0.8355 | 0.014 | -- | -- | 9,830.73 | -92.57 | -54.84 | -110.35 | -62.32 | -64.79 | 6.18 | -6,589.09 | -18,323.42 | 4.43 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
Revance Therapeutics Inc | 243.90m | -283.87m | 543.82m | 597.00 | -- | -- | -- | 2.23 | -3.17 | -3.21 | 2.64 | -1.24 | 0.4466 | 1.35 | 9.18 | 408,542.70 | -51.97 | -55.55 | -61.40 | -63.20 | 71.53 | -- | -116.39 | -304.96 | 3.01 | -22.09 | 1.41 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
Sinovac Biotech Ltd | 429.20m | -130.73m | 639.90m | 3.04k | -- | -- | -- | 1.49 | -1.31 | -1.31 | 4.31 | 86.81 | 0.0322 | 0.2019 | 1.08 | 141,325.00 | -2.23 | 36.14 | -3.30 | 58.37 | 92.09 | 90.77 | -69.19 | 65.87 | 11.24 | -- | 0.0262 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
Avid Bioservices Inc | 142.36m | -144.17m | 660.28m | 371.00 | -- | 11.26 | -- | 4.64 | -2.27 | -2.27 | 2.24 | 0.9192 | 0.3661 | 3.81 | 4.32 | 383,714.30 | -37.08 | -0.826 | -57.59 | -1.20 | 6.27 | 19.26 | -101.27 | -2.14 | 1.05 | -3.18 | 0.7343 | -- | -6.27 | 21.15 | -54,444.79 | -- | 84.15 | -- |
Holder | Shares | % Held |
---|---|---|
Suvretta Capital Management LLCas of 31 Mar 2024 | 4.19m | 9.94% |
Tang Capital Management LLCas of 31 Mar 2024 | 4.13m | 9.78% |
Adage Capital Management LPas of 31 Mar 2024 | 2.58m | 6.10% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 2.23m | 5.29% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.65m | 3.92% |
Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 1.46m | 3.47% |
Saturn V Capital Management LLCas of 31 Mar 2024 | 1.44m | 3.42% |
StemPoint Capital LPas of 31 Mar 2024 | 1.16m | 2.75% |
First Turn Management LLCas of 30 Jun 2024 | 1.06m | 2.51% |
DAFNA Capital Management LLCas of 31 Mar 2024 | 806.97k | 1.91% |